|
|
|
|
|
|
Sponsored by: |
Pfizer |
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00751062 |
PhXA41 is not inferior to timolol in reducing intra-ocular pressure
Condition | Intervention | Phase |
Open Angle Glaucoma Ocular Hypertension |
Drug: timolol Drug: PhXA41 |
Phase III |
Genetics Home Reference related topics: | early-onset glaucoma |
MedlinePlus related topics: | Glaucoma High Blood Pressure |
ChemIDplus related topics: | Latanoprost Timolol Timolol maleate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 6-Month, Randomized, Double-Masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-Centre Study in Scandinavia |
Enrollment: | 267 |
Study Start Date: | November 1992 |
Study Completion Date: | December 1993 |
Primary Completion Date: | December 1993 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Timolol: Active Comparator |
Drug: timolol
One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
|
PhXA41: Experimental |
Drug: PhXA41
One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
|
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Denmark | |||||
Pfizer Investigational Site | |||||
Hellerup, Denmark | |||||
Pfizer Investigational Site | |||||
Vejle, Denmark | |||||
Finland | |||||
Pfizer Investigational Site | |||||
Oulu, Finland | |||||
Norway | |||||
Pfizer Investigational Site | |||||
Trondheim, Norway | |||||
Pfizer Investigational Site | |||||
Oslo, Norway | |||||
Pfizer Investigational Site | |||||
Bergen, Norway | |||||
Sweden | |||||
Pfizer Investigational Site | |||||
Uppsala, Sweden | |||||
Pfizer Investigational Site | |||||
Huddinge, Sweden, 141 86 | |||||
Pfizer Investigational Site | |||||
Linkoping, Sweden, 581 85 | |||||
Pfizer Investigational Site | |||||
Lund, Sweden | |||||
Pfizer Investigational Site | |||||
Malmo, Sweden, 205 02 | |||||
Pfizer Investigational Site | |||||
Umea, Sweden | |||||
Pfizer Investigational Site | |||||
Gothenburg, Sweden |
Pfizer |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
To obtain contact information for a study center near you, click here. 
  |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | 9200PG006, A6111130 |
First Received: | September 10, 2008 |
Last Updated: | September 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00751062 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|